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Thyroid carcinomas often recur many years after surgery (Loh 
et al, 1997). The monitoring of serum thyroglobulin (TG) by
immunoassay can be used in detecting residual or recurrent differ-
entiated thyroid carcinoma (DTC) after total thyroidectomy.
However, the usefulness of this method is limited by both the
requirement for thyroid hormone withdrawal to attain optimal
sensitivity and interference by antithyroglobulin antibodies
(Singer et al, 1996). Recent reports have demonstrated that the
reverse transcription-polymerase chain reaction (RT-PCR) can be
used to detect circulating cancer cells in the peripheral blood of
patients with malignancies such as prostate cancer (Ghossein et al,
1995) and neuroblastoma (Mattano et al, 1992). 
A sensitive RT-PCR assay amplifying thyroid-specific mRNAs
such as TG or thyroid peroxidase (TPO) may be utilized for the
early detection of DTC recurrence and thus may have important
therapeutic and prognostic implications. In fact, 2 recent reports
have shown the clinical usefulness of the RT-PCR detection of TG,
TPO, and ret/PTC in the follow-up of DTC (Ringel et al, 1998;
Tallini et al, 1998). For example, TG mRNA in peripheral blood
became detectable earlier than serum TG in a case of recurrent
thyroid papillary carcinoma. Recently, Ringel et al have reported
the clinical usefulness of the real-time quantitative measurement
of TG mRNA in the peripheral blood of the patients with DTC. In
their report, however, they did not use an appropriated internal
reference such as glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA (Ringel et al, 1999). 
Encouraged by these optimistic reports, we applied this method
to our patients for the follow-up of DTC. However, we found that
TG and TPO mRNAs were detectable in the peripheral blood of all
the patients tested, a result that differs from those reported previ-
ously, and we therefore felt a need to re-evaluate TG mRNA detec-
tion. One of the problems of previous studies has been that the
expressions levels of TG mRNA have not been calculated in
conjunction with the use of an appropriate internal control, as the
results of simple RT-PCR detection can vary in response to subtle
changes in conditions. 
Patients who have undergone total thyroidectomy constitute
good model cases for evaluating this problem. As such, we
measured TG mRNA in the peripheral blood of patients after total
thyroidectomy and determined the expression levels of TG mRNA
by real time-quantitative RT-PCR using GAPDH mRNA as an
internal control. 
SUBJECTS AND METHODS 
Patients 
We evaluated 57 patients (3 males and 54 females, between 15 and
77 years of age, 49 papillary, 4 follicular, and 4 medullary carci-
nomas) who underwent total thyroidectomy. Blood was drawn at
least 6 months after surgery or the administration of radioactive
iodine. Of the 53 DTC patients, 21 had evident metastases (16
lung, 1 bone, 2 mediastinum, and 2 lung and bone) detected by
either computed tomography or 131I scintigram. All the patients
with metastasis and 21 of 32 patients without metastasis received
5 to 150 (mean: 55.7 mCi) and 5 to 100 (mean: 17.0 mCi) 131I,
respectively. All the patients after total thyroidectomy, except
those with medullary carcinoma, received a suppressive dose of
thyroxine so that their serum thyroid stimulating hormone (TSH)
levels were undetectable. 17 healthy subjects (5 males and 12
females, between 29 and 59 years of age) with no evidence of
thyroid disease were also examined as controls. The protocol was
approved by the institutional review boards at the participating
institutions, and informed consent was obtained. 
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Peripheral blood was collected in heparinized tubes in 10 ml
samples and placed immediately on ice. Next, 10 ml of 3% dextran
200 000 (WAKO, Osaka, Japan) was added to the tubes, which
were than placed in ice for 30 min. The supernatant was collected
and centrifuged. The precipitant was dispersed in distilled water to
lyse the remaining erythrocytes, and an equal volume of 1.8%
NaCl was then immediately added. The isolated cells were
washed, then centrifuged. Total RNA was extracted following
standard procedures (Chomczynski and Sacchi, 1987) and
resolved in 20 ml of distilled water, then stored at –70˚C. 
Reverse transcription 
1 ml of total RNA was reverse transcribed in an RT mixture
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM dithio-
threitol, 3 mM MgCl2, 0.5 mM deoxynucleotide triphosphates
(dNTPs), 200 U M-MLV reverse transcriptase (Gibco,
Gaithersburg, MD), 2 U ml–1 RNase inhibitor (Takara, Shiga,
Japan), and 2.5 mM random hexamer (Takara) in a total volume of
20 ml at 42˚C for 60 min. 
RT-PCR detection of TG mRNA 
1 ml of first-strand cDNA was used as a template for the PCR reac-
tion with specific primers for TG cDNA as previously described
(Tallini et al, 1998). Each reaction mixture consisted of 1 ml of
cDNA, 0.5 mM of each primer, 1 ml of 10 ´ Ex Taq Buffer, 0.8 ml
of 2.5 mM dNTP mix, 0.5 U of Ex Taq polymerase, and nuclease-
free water to a final volume of 10 ml. 10 ´ Ex Taq Buffer, dNTP
mix, and Ex Taq polymerase were obtained from Takara. The
reaction mixture was then subjected to 35 cycles of denatura-
tion (94˚C, 1 min), annealing (55˚C, 1 min) and extension (72˚C,
1 min). After PCR amplification, the reaction mixture was run on a
2% SeaKem GTG agarose gel (Takara). The gel was then stained
with ethidium bromide. Samples without reverse transcription
were used as negative controls. 
Real-time quantitative RT-PCR 
Real-time quantitative RT-PCR (TaqMan PCR) of TG and
GAPDH mRNAs using an ABI PRISM 7700 Sequence Detection
System and a TaqMan PCR Core Reagent Kit (PE Biosystems,
Foster City, CA) was performed as previously described (Takano
et al, 1999). The primers used for amplification of TG cDNA were
changed to the same set of primers used in the report by Tallini et
al. The probe for TG cDNA used for the TaqMan PCR was: (5¢-
FAM-CACTTCGAGTTCCAGGAATGGCCTGACCCT-
TAMRA-3¢). 
1 ml of each cDNA was used for measurement of the copy
number. The conditions for the TaqMan PCR were as follows:
95˚C for 10 min, followed by 40 cycles of 95˚C for 15 seconds
and 60˚C for 1 min. Recombinant pGEM T-vectors (Promega,
Tokyo, Japan) containing TG or GAPDH cDNA were
constructed by PCR cloning with the same set of primers used in
the TaqMan PCR and were used as standard samples. The
expression levels of TG mRNA were calculated by dividing the
copy number of TG mRNA by that of GAPDH mRNA.
Intraassay variabilities were 35% and 24% at 10 and 100 ng l–1
thyroid total RNA, respectively. Interassay variabilities across a
1-month period were 38% and 28% at 10 and 100 ng/L thyroid
total RNA, respectively. 
Extraction of total RNA from a normal thyroid tissue 
A portion of normal thyroid tissue from the opposite lobe of a
thyroid papillary carcinoma was obtained by surgery. Total RNA
was extracted following standard procedures. 
Serum TG measurement 
Serum TG was measured using a commercial radioimmunoassay
kit (Ab-Beads Thyroglobulin, Eiken, Tokyo, Japan). Intrassay
variability was 8.6% at 5 mgl –1. Interassay variabilities across a 1-
month period were 11.8%, 7.4%, 3.1% at 15, 15, 50 mgl –1, respec-
tively. Assay sensitivity as determined from the 20% interassay
coefficient of variation (CV) was 0.5 mgl –1. The cut off level of
this kit was 28.4 mgl –1. Serum anti-TG antibody was detected with
a semi-quantitative microtitre particle agglutination test for the in
vitro diagnostic detection and titration of anti-TG antibodies in
human serum, SERODIA-ATG (Fujirebio, Tokyo, Japan). 
Statistical analysis 
Statistical analysis of differences between the groups was carried
out using the Mann–Whitney U test. Linear correlation analysis
was used to examine the correlation between serum TG and
expression levels of TG mRNA in the peripheral blood. Ps of
<0.05 were considered significant. 
RESULTS 
TG mRNA was detected in all the samples tested, including the
samples from 4 patients diagnosed with medullary carcinoma.
Representative data are shown in Figure 1. 
The reliability of the quantitative RT-PCR was estimated by
adding total RNA from a normal thyroid to that from 10 ml of
blood of a healthy subject. The TG/GAPDH mRNA ratio in the
sample without the addition of thyroid RNA was 6.75 ´ 10-5. As
the thyroid RNA was increased from 10 ng per 1 l blood to 10 mg
per 1 l blood, a linear increase in the TG/GAPDH mRNA ratio was
observed, indicating the reliability of this quantitative measure-
ment (Figure 2). These results were used in the construction of the
standard curve in the following experiments. 
Using this method, the expression levels of TG mRNA in the
peripheral blood of 57 patients and 17 healthy subjects were calcu-
lated. All the samples were successfully measured by real-time
quantitative RT-PCR, which confirmed the expression of TG
mRNA in all the samples. There was no statistical difference
between the patients with and without metastasis (Figure 3). The
serum TG was measured in the 49 DTC patients without serum
anti-TG antibody, and the set of results were compared (Figure 4).
No statistical differences in the TG mRNA levels were observed.
While serum TG was detectable in all the patients with metastasis,
it was undetectable in 14 of 29 patients without metastasis.
Further, serum TG was undetectable in all 4 patients diagnosed
with medullary carcinoma, while quantitative measurement of TG
mRNA was possible (Figure 3). These results suggest that serum
TG is a superior marker of distant metastasis of DTC than TG
mRNA in peripheral blood. Further, the correlation between TG
TG mRNA in peripheral blood 103
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mRNA and serum TG was estimated in these 49 patients and no
correlation was observed between the two (Figure 5). 
DISCUSSION 
The vast majority of thyroid carcinomas are differentiated 
tumours that originate from the follicular epithelium and show
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Figure 1 Expression of TG mRNA in the peripheral blood of a patient
diagnosed with medullary carcinoma after total thyroidectomy. After extraction
of total RNA from the peripheral blood, RT-PCR amplifying TG cDNA was
performed (Lane 3). Lane 2 shows the results using the same sample without
the addition of reverse transcriptase. Lane 1; PHY maker (Takara) 
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Figure 2 Real-time quantitative RT-PCR of TG mRNA in peripheral blood.
Total RNA from a normal thyroid was added to that from 10 ml of blood from
a healthy subject, after which real-time quantitative RT-PCR, as described in
Methods was carried out. The copy number of GAPDH mRNA was
simultaneously measured, and the expression levels of TG mRNA were
calculated as the ratio of TG and GAPDH mRNA. The results are shown with
mean ±SD for triplicate determinations
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Figure 3 TG mRNA in peripheral blood of the patients after total
thyroidectomy. The expression levels of TG mRNA in the peripheral blood of
healthy subjects (N), the patients of DTC after total thyroidectomy (DTC) with
or without distant metastasis, and patients of medullary carcinoma (M) were
measured. The results are shown with means for duplicate determinations 
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Figure 4 Comparison of serum TG (A) and TG mRNA (B) in the patients
with (+) or without (–) metastasis TG mRNA in peripheral blood 105
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either follicular or papillary structure. Serum TG immunodetec-
tion measurements are currently the best available indicator of
tumour metastases, even though their diagnostic usefulness has
several limitations. 
Circulating tumour cells can be detected by sensitive PCR
amplification of tumour-specific abnormal gene sequences or
through the detection of tissue-specific abnormal gene transcripts
normally absent in the peripheral blood. Thyroid tumours repre-
sent the ideal target for such studies because they actively express
tissue-specific markers such as TG and TPO. Despite promising
reports in 1998 on the detection of TG mRNA in peripheral blood,
our preliminary study showed that TG transcripts were detectable
in all samples tested, including the ones from healthy subjects.
Recently, 2 studies suggesting limitations in the clinical applica-
tions of this method have been reported. Wingo et al have detected
TG transcripts in the peripheral blood of healthy subjects that can
be measured by real-time quantitative RT-PCR (Wingo et al,
1999). Bojunga et al have found that TG mRNA expression is not
specific to thyroid tissue and is not correlated with a diagnosis of
thyroid cancer in patients, and they have recommended further
examination of this method by quantitative measurement (Bojunga
et al, 2000). We therefore decided to re-evaluate this method using
samples obtained from patients after total thyroidectomy, in which
TG transcripts in the circulating thyroid cells from the normal
thyroid may be negligible. We detected TG transcripts in all the
samples tested, even in that of the patient diagnosed with
medullary carcinomas, in whom the circulating of thyroid follic-
ular cells was not likely to occur. Real-time quantitative RT-PCR
assay confirmed the expression of TG mRNA in these samples, in
which an increase in the fluorescent signal from hybridized TG
cDNA-specific probe was observed. 
By real-time quantitative RT-PCR, high levels of TG mRNA
were expressed in some patients without evident metastasis. For
example, in one patient, the copy number of TG mRNA in 1 ml of
peripheral blood was comparable to that in over 300 pg total RNA
from normal thyroid tissue, which is approximately equal to 30
thyroid cells. It is hard to believe that this many thyroid cells still
circulated in the peripheral blood of a patient after thyroidectomy
without any evidence of a distant metastasis, which could be a
source of circulating cells. TSH receptor mRNA, which has previ-
ously been considered to be expressed only in the thyroid, was
found to be expressed in adipocytes and lymphocytes (Francis et
al, 1991; Endo et al, 1995). The TG mRNA detected by our study
thus might not have been derived from thyroid cells; instead, it is
most likely that lymphocytes express small quantities of TG
mRNA, as they are known to express various kinds of mRNAs
such as alpha-fetoprotein (AFP) or carcinoembryonic antigen
(CEA) (Lafarge-Frayssinet et al, 1989; Coutelier et al, 1994),
which used to be considered tumour-specific. Further, the expres-
sion of TG mRNA is not likely to be limited to thyroid follicular
cells, as we have recently found it to be expressed in cell lines
derived from lung or gastric carcinomas (data not shown).
Possibly, the regulation of TG mRNA expression in lymphocytes
is controlled by some unknown factors. If so, the detection of TG
mRNA is not likely to become an alternative means of achieving
early detection of recurrent thyroid carcinomas because sensitive
detection of recurrence would be interfered with by basal expres-
sion of TG mRNA in peripheral blood. 
It therefore seems likely that the diagnostic methods presented
by Tallini and Ringel may be useful only in limited populations of
patients in whom a considerable number of thyroid tumour cells
expressing a high copy number of TG mRNA are circulating. In
fact, our results showed no statistical difference between the
samples from patients with or without distant metastasis. Further,
we obtained no evidence that this method is superior to the
conventional measurement of serum TG, as it was hard to utilize
the TG mRNA data to differentiate the patients with metastasis
from those without, whereas serum TG measurements showed
more than 5 mgl –1 in all patients with distant metastasis, and the
high values of interassay CV in the quantitative measurement of
TG mRNA can be a disadvantage in the follow-up of a patient for
a long period. Moreover, TG mRNA and serum TG measured in
the same samples showed no significant correlation. These results
suggest that the sources of TG mRNA and serum TG might be
different, and, as discussed above, the former might not be derived
from thyroid follicular cells. 
The use of TPO mRNA in the detection of thyroid carcinomas
has also been reported in conjunction with some studies. However,
our preliminary data showed that TPO mRNA was detectable by
RT-PCR in all the samples tested, including those from healthy
subjects and patients after total thyroidectomy without distant
metastasis (data not shown). Considering that TPO mRNA are
usually less abundant than TG mRNA in thyroid cells, it is not
likely that the use of TPO mRNA instead of TG would improve
the clinical usefulness of this method. 
In summary, we have found no advantages in diagnosing DTC
by the quantitative measurement of TG mRNA in peripheral
blood. We consider that an intensive re-evaluation, including a
determination of what percentage of TG mRNA derives from
thyroid follicular or cancer cells, is necessary with regard to this
method before considering the clinical applications. 
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